A5025914671- Obsessive-Compulsive Spectrum Disorders
- Autism Spectrum Disorder Research
- Attention Deficit Hyperactivity Disorder
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Body Image and Dysmorphia Studies
- Genetics and Neurodevelopmental Disorders
- Gambling Behavior and Treatments
- Eating Disorders and Behaviors
- Personality Disorders and Psychopathology
- Sexuality, Behavior, and Technology
- Child and Adolescent Psychosocial and Emotional Development
- Neurotransmitter Receptor Influence on Behavior
- Child Nutrition and Feeding Issues
- Bipolar Disorder and Treatment
- Schizophrenia research and treatment
- Neuroendocrine regulation and behavior
- Mental Health and Psychiatry
- Psychosomatic Disorders and Their Treatments
- Behavioral and Psychological Studies
- Child Development and Digital Technology
- Transcranial Magnetic Stimulation Studies
- Infant Health and Development
- Neurological disorders and treatments
- Genetic Syndromes and Imprinting
- Tattoo and Body Piercing Complications
Montefiore Medical Center
2015-2024
Albert Einstein College of Medicine
2015-2024
Purdue University West Lafayette
2024
Ben-Gurion University of the Negev
2015-2019
Advanced Mental Health Care
2019
Tel Aviv University
2019
University of California, Los Angeles
2019
Icahn School of Medicine at Mount Sinai
2003-2017
The Bronx Defenders
2016
Spectrum Neuroscience and Treatment Institute
2013-2015
In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress (PTSD) are presented. Since publication first version guideline, substantial number new randomized controlled studies anxiolytics have been published. particular, more relapse prevention now available that show sustained efficacy anxiolytic...
<h3>Context</h3> Selective serotonin reuptake inhibitors are widely prescribed for children with autism spectrum disorders. <h3>Objectives</h3> To determine the efficacy and safety of citalopram hydrobromide therapy repetitive behavior in <h3>Design</h3> National Institutes Health–sponsored randomized controlled trial. <h3>Setting</h3> Six academic centers, including Mount Sinai School Medicine, North Shore–Long Island Jewish Health System, University Carolina at Chapel Hill, California Los...
Seventy-four patients who met DSM-III criteria for social phobia completed 8 weeks of double-blind, randomly assigned treatment with the monoamine oxidase inhibitor phenelzine sulfate, cardioselective beta-adrenergic blocker atenolol, or placebo. The overall response rates were 64% phenelzine, 30% and 23% Phenelzine was widely superior to both atenolol placebo on independent rater analyses and, a lesser extent, self-report, no significant differences between At end 16 weeks, still...
Cytoarchitectonic changes in the anterior cingulate cortex, hippocampus, subiculum, entorhinal amygdala, mammillary bodies, and septum were reported a postmortem study of autism. Previously, authors found smaller volume decreased metabolism seven autistic patients. In this study, they measured glucose gyrus an expanded group 17 patients with autism spectrum disorders (autism [N=10] or Asperger's disorder [N=7]) age- sex-matched healthy volunteers.Subjects performed serial verbal learning...
We investigated the effects of intranasal oxytocin (OXT) on trust and cooperation in borderline personality disorder (BPD), a marked by interpersonal instability difficulties with cooperation. Although studies healthy adults show that OXT increases trust, individuals BPD may an altered response to exogenous because pro-social behavior vary depending relationship representations expectations people possess and/or system functioning BPD. control participants received played social dilemma game...
Objective. Anxiety disorders are frequently under-diagnosed conditions in primary care, although they can be managed effectively by general practitioners. Methods. This paper is a short and practical summary of the World Federation Biological Psychiatry (WFSBP) guidelines for pharmacological treatment anxiety disorders, obsessive–compulsive disorder (OCD) posttraumatic stress (PTSD) care. The recommendations were developed task force 30 international experts field based on randomized...
Major depressive disorder (MDD) is a prevalent and disabling condition, many patients do not respond to available treatments. Deep transcranial magnetic stimulation (dTMS) new technology allowing non-surgical of relatively deep brain areas. This the first double-blind randomized controlled multicenter study evaluating efficacy safety dTMS in MDD. We recruited 212 MDD outpatients, aged 22–68 years, who had either failed one four antidepressant trials or tolerated at least two treatments...
OBJECTIVE: Pathological gambling is a disabling disorder experienced by approximately 1%–2% of adults and for which there are few empirically validated treatments. The authors examined the efficacy tolerability opioid antagonist nalmefene in treatment with pathological gambling. METHOD: A 16-week, randomized, dose-ranging, double-blind, placebo-controlled trial was conducted at 15 outpatient centers across United States between March 2002 April 2003. Two hundred seven persons DSM-IV were...
Obsessive-compulsive disorder (OCD) is a chronic and disabling condition that often responds unsatisfactorily to pharmacological psychological treatments. Converging evidence suggests dysfunction of the cortical-striatal-thalamic-cortical circuit in OCD, previous feasibility study indicated beneficial effects deep transcranial magnetic stimulation (dTMS) targeting medial prefrontal cortex anterior cingulate cortex. The authors examined therapeutic effect dTMS multicenter double-blind...
There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature this area is sparse. Emerging data from animal models genetic association studies as well early, single-dose suggest that oxytocin system may be a potential therapeutic target ASD. The primary aim study was to examine safety/therapeutic effects intranasal versus placebo adults with ASD, respect two core symptom domains...